含砷剂方案治疗急性早幼粒细胞白血病的分析

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (680 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To retrospectively analyze the difference in clinical efficacy and cost between Arsenic-containing agent and non-arsenic-containing agent in patients with acute promyelocytic leukemia. Methods From December 2012 to December 2016, a total of 27 cases of adult acute promyelocytic leukemia patients primary treated in Affiliated Hospital of Guilin Medical University were selected. According to the different induction program, they were divided into observation group (12 cases) and control group (15 cases). The observation group was treated with arsenic-containing agent and the control group was treated with non-arsenic-containing agent. The differences of efficacy and adrerse reactions, blood dosage and medical expenses between the two groups were compared. Results There was no statistically significant difference between the two groups in the rates of complete remission, the time required to obtain CR, the 2-year overall survival rate, the dosage of red blood cells, platelets and plasma, the duration of treatment, and the cost of treatment (all P > 0.05). Conclusion The efficacy and cost of induction therapy in patients with acute promyelocytic leukemia with arsenic-containing agent is similar to that with non-arsenic-containing agent, but it′s necessary to study the large size sample further.

Key words： Acute promyelocytic leukemia Inductive scheme Arsenic agent Treatment Cost

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Feng1 JIA Haipeng2 DUAN Yanchao2

Cite this article:

LIU Feng1 JIA Haipeng2 DUAN Yanchao2. Analysis on the treatment of acute promyelocytic leukemia with arsenic-containing agent regimen[J]. 中国医药导报, 2020, 17(11): 61-64,75.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I11/61

[1] 沈志祥，黄晓军，马军，等.中国急性早幼粒细胞白血病诊疗指南（2018年版）[J].中华血液学杂志，2018，39（3）：179-183.
[2] O′Donnell MR，Abboud CN，Altman J，et al. NCCN Clinical Practice Guidelines Acute myeloid leukemia [J]. J Nati Compr Canc Netw，2012，10（8）：984-1021.
[3] 王绅，宗秀芳.全反式维甲酸联合亚砷酸治疗儿童急性早幼粒细胞白血病疗效分析[J].现代肿瘤医学，2015，23（7）：2056-2058.
[4] 急性早幼粒细胞白血病临床路径[S].2009年版.中华人民共和国卫生部，2009：2-4.
[5] 张之南、沈悌．血液病诊断及疗效标准[M].3版.北京：科学出版社，2007：106-108，141-133.
[6] Huang BT，Zeng QC，Zhao WH，et al. A prospective，observational study of added medium dose cytosine arabinoside versus As2O3 for elderly patients with acute promyelocytic leukemia [J]. Med Oncol，2014，31：233.
[7] 张迎媚，陈波，吴龙月，等.急性早幼粒细胞白血病合并弥散性血管内凝血亚砷酸诱导治疗疗效分析[J].现代生物医学进展，2018，18（4）：1498-1501.
[8] 戴丹，徐燕丽.全反式维甲酸、三氧化二砷、去甲氧柔红霉素治疗初治成人急性早幼粒细胞白血病的疗效观察[J].内科急危重症杂志，2015，21（1）：70-71.
[9] Abedin S，Altman JK. Acute promyelocytic leukemia：preventing early complications and late toxicities [J]. Hematology Am Soc Hematol Educ Program，2016，11（1）：10-15.
[10] Koehler M，Fischer T. How health related quality of life outcomes in patients with acute promyelocytic leukemia can help physicians in decision making [J]. J Clin Oncol，2015，33（9）：1090-1091.
[11] 裴仁治，莫淑萍，胡慧仙，等.初发急性早幼粒细胞白血病不同治疗方案疗效比较[J].中国实用内科杂志，2015， 35（10）：862-864.
[12] Cicconi L，LoCoco F. Current management of newly diagnosed acute promyelocytic leukemia [J]. Ann Oncol，2016，27（8）：1474-1481.
[13] Mc Culloch D，Brown C，Iland H. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia：current perspectives [J]. Onco Targets Ther，2017，10：1585-1601.
[14] Liu X，Chen J，Yu S，et al. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells [J]. Cell Death Dis，2017，8（5）：e2782.doi：10.1038/cddis.2017. 197.
[15] Zhang X，Pan J. Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia [J]. Ann Hematol，2017，96（4）：707-708. doi：10.1007/s00277-017-2923-z.
[16] Baba SM，Shah ZA，Pandith AA，et al. Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic trioxide [J]. Cancer Genet，2019，231-232：14-21. doi：10.1016/j.cancergen.2018. 12.003.
[17] Gao N，Wang XX，Sun JR，et al. Clinical impact of galectin-3 in newly diagnosed t（15；17）（q22；q21）/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens [J]. Ann Hematol，2017，96（5）：711-718. doi：10.1007/s00277-017-2948-3.
[18] Hu J，Sun Q，Fang W，et al. Effect of combination of all-trans retinoic acid and arsenic trioxide on apoptosis of acute promyelocytic leukemia cells [J]. Cell mol biol （Noisy-le-Grand，France），2019，65（4）：97-100. doi：10. 14715/cmb/2019.65.4.16.
[19] Jain P，Konoplev S，Benjamini O，et al. Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide （As2O3） and all-trans retinoic acid （ATRA） [J]. Blood Res，2018，53（2）：169-172. doi：10.5045/br.2018. 53.2.169.
[20] Nagao R，Hosoba R，Yahagi Y，et al. All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis [J]. Rinsho Ketsueki，2019，60（10）：1431-1435. doi：10.11406/rinketsu.60.1431.
[21] Coombs CC，Tavakkoli M，Tallman MS. Acute promyelocytic leukemia：where did we start，where are we now，and the future [J]. Blood Cancer J，2015，25（5）：e304.
[22] Zhang L，Zou Y，Chen Y，et al. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide：a randomized controlled trial [J]. BMC Cancer，2018，18（1）：374. doi：10.1186/s12885-018-4280-2.
[23] Laura C，Massimo B，Luca F，et al. Prolonged treatment with arsenic trioxide （ATO） and all-trans retinoic acid （ATRA） for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy [J]. Ann Hematol，2018，97（10）：1797-1802. doi：10.1007/s00277-018-3400-z.
[24] Shah G，Mikhail FM，Bachiasvili K，et al. Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide （ATO）/all trans retinoic acid （ATRA） based induction and consolidation without maintenance phase：A case Series [J]. Hematol Oncol Stem Cell Ther，2019，14（10）. pii：S1658-3876（19）30076-7. doi：10.1016/j.hemonc.2019.08.006.
[25] 陈娟，卢红.ATO与ATRA联合小剂量HHT治疗急性早幼粒细胞白血病的临床疗效[J].西部医学，2015，27（9）：536-540.
[26] Bin L，Zhouyi Z，Yifen S，et al. Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy [J]. Onco Targets Ther，2017，10（4）：2305-2313. doi：10.2147/OTT. S135013. eCollection 2017.
[27] Yinjun L，Ying L，Zhijuan Z，et al. Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy [J]. Hematol Oncol，2018（6）. doi：10.1002/hon.2519.
[28] Autore F，Chiusolo P，Sorà F，et al. Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid [J]. Leuk Lymphoma，2019，60（5）：1328-1330. doi：10.1080/10428194.2018.1522436.